Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Accounts Payables: 2009-2025

Historic Accounts Payables for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $468.0 million.

  • UNITED THERAPEUTICS's Accounts Payables rose 28.61% to $468.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $468.0 million, marking a year-over-year increase of 28.61%. This contributed to the annual value of $344.5 million for FY2024, which is 15.60% up from last year.
  • According to the latest figures from Q3 2025, UNITED THERAPEUTICS's Accounts Payables is $468.0 million, which was up 8.33% from $432.0 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Accounts Payables ranged from a high of $468.0 million in Q3 2025 and a low of $165.0 million during Q1 2021.
  • For the 3-year period, UNITED THERAPEUTICS's Accounts Payables averaged around $342.6 million, with its median value being $333.4 million (2023).
  • Per our database at Business Quant, UNITED THERAPEUTICS's Accounts Payables dropped by 6.63% in 2021 and then skyrocketed by 51.48% in 2023.
  • UNITED THERAPEUTICS's Accounts Payables (Quarterly) stood at $174.6 million in 2021, then spiked by 31.67% to $229.9 million in 2022, then increased by 29.62% to $298.0 million in 2023, then climbed by 15.60% to $344.5 million in 2024, then grew by 28.61% to $468.0 million in 2025.
  • Its last three reported values are $468.0 million in Q3 2025, $432.0 million for Q2 2025, and $367.0 million during Q1 2025.